{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:41:11Z","timestamp":1772757671523,"version":"3.50.1"},"reference-count":76,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pulmonary Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1016\/j.pupt.2006.05.005","type":"journal-article","created":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T21:11:45Z","timestamp":1149196305000},"page":"290-303","source":"Crossref","is-referenced-by-count":49,"title":["Advances in asthma and COPD management: Delivering CFC-free inhaled therapy using Modulite\u00ae technology"],"prefix":"10.1016","volume":"20","author":[{"given":"D.","family":"Acerbi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Brambilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Kottakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2006.05.005_bib1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD) Scientific Committee. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Pocket guide to COPD diagnosis, management and prevention. A Guide for Health Care Professionals 2003 (Updated 2004). Available at: www.goldcopd.com\/"},{"key":"10.1016\/j.pupt.2006.05.005_bib2","unstructured":"Global Initiative for Asthma. Pocket guide for asthma management and prevention (Updated 2004). Available at: www.ginasthma.com"},{"issue":"4","key":"10.1016\/j.pupt.2006.05.005_bib3","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1006\/pupt.2002.0381","article-title":"Global initiat ive for chronic obstructive lung diseases (GOLD)","volume":"15","author":"Hurd","year":"2002","journal-title":"Pulm Pharmacol Ther"},{"issue":"Suppl. 1","key":"10.1016\/j.pupt.2006.05.005_bib4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1046\/j.1365-2222.2000.00088.x","article-title":"Global initiative for asthma (GINA) and its objectives","volume":"30","author":"Bousquet","year":"2000","journal-title":"Clin Exp Allergy"},{"issue":"Suppl. 1","key":"10.1016\/j.pupt.2006.05.005_bib5","first-page":"i1","article-title":"British guidelines on the management of asthma","volume":"58","year":"2003","journal-title":"Thorax"},{"issue":"Suppl. 1","key":"10.1016\/j.pupt.2006.05.005_bib6","first-page":"1","article-title":"Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care","volume":"59","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.pupt.2006.05.005_bib7","unstructured":"Ozone Secretariat United Nations Environment Programme. The Secretariat for The Vienna Convention for the Protection of the Ozone Layer & The Montreal Protocol on Substances that Deplete the Ozone Layer. The Montreal Protocol on Substances that Deplete the Ozone Layer 2000. Available at: www.unep.org\/ozone\/pdf\/Montreal-Protocol2000.pdf"},{"issue":"1","key":"10.1016\/j.pupt.2006.05.005_bib8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/00151829-200403010-00005","article-title":"Hydrofluoroalkane formulations of inhaled corticosteroids for the treatment of asthma","volume":"3","author":"Zeidler","year":"2004","journal-title":"Treat Respir Med"},{"issue":"Suppl. D","key":"10.1016\/j.pupt.2006.05.005_bib9","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0954-6111(02)80018-X","article-title":"Modulite: a means of designing the aerosols generated by pressurized metered dose inhalers","volume":"96","author":"Ganderton","year":"2002","journal-title":"Respir Med"},{"key":"10.1016\/j.pupt.2006.05.005_bib10","first-page":"395","article-title":"Pharmacokinetics of a new CFC-free metered dose inhaler of beclomethasone dipropionate following multiple dosing in asthmatic patients","volume":"2","author":"Acerbi","year":"2000","journal-title":"Resp Drug Deliv VIII"},{"issue":"Suppl. D","key":"10.1016\/j.pupt.2006.05.005_bib11","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0954-6111(02)80019-1","article-title":"Modulite technology: pharmacodynamic and pharmacokinetic implications","volume":"96","author":"Woodcock","year":"2002","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.pupt.2006.05.005_bib12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0378-5173(99)00137-4","article-title":"Modulation of aerosol clouds produced by pressurised inhalation aerosols","volume":"186","author":"Brambilla","year":"1999","journal-title":"Int J Pharm"},{"key":"10.1016\/j.pupt.2006.05.005_bib13","unstructured":"Ganderton D, Lewis D, Meakin B, et al. The modulation of clouds generated by pMDIs [abstract plus poster]. Presented at the 12th Biennial Congress of the International Society for Aerosols in Medicine (ISAM), Vienna, Austria, June 12\u201316, 1999."},{"issue":"1","key":"10.1016\/j.pupt.2006.05.005_bib14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0378-5173(00)00401-4","article-title":"Transition to CFC-free metered dose inhalers\u2014into the new millennium","volume":"201","author":"McDonald","year":"2000","journal-title":"Int J Pharm"},{"issue":"Suppl. D","key":"10.1016\/j.pupt.2006.05.005_bib15","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.rmed.2003.10.003","article-title":"The formulation and evaluation of a CFC-free budesonide pressurised metered dose inhaler","volume":"97","author":"Ganderton","year":"2003","journal-title":"Respir Med"},{"key":"10.1016\/j.pupt.2006.05.005_bib16","first-page":"85","article-title":"Biopharmaceutical optimisation of a new CFC-free budesonide pMDI [abstract plus poster]","volume":"VIII","author":"Acerbi","year":"2002","journal-title":"Respir Drug Deliv"},{"issue":"Suppl. D","key":"10.1016\/j.pupt.2006.05.005_bib17","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S0954-6111(02)80020-8","article-title":"Clinical studies in asthmatics with a new non-extra fine HFA formulation of beclometasone dipropionate (BDP Modulite)","volume":"96","author":"Bousquet","year":"2002","journal-title":"Respir Med"},{"issue":"Suppl. D","key":"10.1016\/j.pupt.2006.05.005_bib18","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.rmed.2003.10.001","article-title":"Efficacy and safety of inhaled budesonide delivered once or twice daily via HFA-134a in mild to moderate persistent asthma in adult patients. Comparison with budesonide CFC","volume":"97","author":"Vastagh","year":"2003","journal-title":"Respir Med"},{"issue":"4","key":"10.1016\/j.pupt.2006.05.005_bib19","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1365-2125.2004.02172.x","article-title":"Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study","volume":"58","author":"Houghton","year":"2004","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl. 1","key":"10.1016\/j.pupt.2006.05.005_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000083686","article-title":"Modulite\u00ae: a simple solution to a difficult problem","volume":"72","author":"Lewis","year":"2005","journal-title":"Respiration"},{"key":"10.1016\/j.pupt.2006.05.005_bib21","unstructured":"Brambilla G, Davies RJ, Ferraris A, et al. Plume profiling of beclomethasone dipropionate pMDIs [abstract plus poster]. Presented at the 13th International Congress of the International Society for Aerosols in Medicine (ISAM), Interlaken, Switzerland, September 17\u201321, 2001."},{"key":"10.1016\/j.pupt.2006.05.005_bib22","series-title":"Airflow resistance of different inhalation devices and visualization of the aerosol plume emitted by different metered dose inhalers","author":"Sommerer","year":"2005"},{"key":"10.1016\/j.pupt.2006.05.005_bib23","unstructured":"European Directorate for the Quality of Medicines. European pharmacopeia, 4th ed. Strasbourg, France, 2002."},{"issue":"6","key":"10.1016\/j.pupt.2006.05.005_bib24","first-page":"623","article-title":"Metered-dose inhalers, dry powder inhalers, and transitions","volume":"45","author":"Fink","year":"2000","journal-title":"Respir Care"},{"issue":"5","key":"10.1016\/j.pupt.2006.05.005_bib25","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1152\/japplphysiol.00525.2003","article-title":"Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols","volume":"95","author":"Usmani","year":"2003","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.pupt.2006.05.005_bib26","series-title":"Pharmaceutical inhalation aerosol technology","first-page":"255","article-title":"Summary of common approaches to pharmaceutical aerosol administration","author":"Hickey","year":"1992"},{"issue":"1","key":"10.1016\/j.pupt.2006.05.005_bib27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1089\/jam.2005.18.45","article-title":"Optimum peripheral drug deposition in patients with cystic fibrosis","volume":"18","author":"Brand","year":"2005","journal-title":"J Aerosol Med"},{"issue":"3","key":"10.1016\/j.pupt.2006.05.005_bib28","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/jam.1989.2.285","article-title":"Intercomparison of experimental regional aerosol deposition data","volume":"2","author":"Stahlhofen","year":"1989","journal-title":"J Aerosol Med"},{"issue":"7","key":"10.1016\/j.pupt.2006.05.005_bib29","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/jps.10152","article-title":"Factors affecting the deposition of inhaled porous drug particles","volume":"91","author":"Musante","year":"2002","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.pupt.2006.05.005_bib30","unstructured":"Acerbi D, Poli G, Haussermann S, et al. Lung deposition of formoterol HFA in healthy volunteers, asthmatic and COPD patients [abstract plus poster]. Presented at the European Respiratory Society Annual Congress (ERS), Copenhagen, Denmark, September 17\u201321, 2005."},{"key":"10.1016\/j.pupt.2006.05.005_bib31","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1513\/pats.200404-030MS","article-title":"Imaging drug delivery and drug responses in the lung","volume":"1","author":"Dolovich","year":"2004","journal-title":"Proc Am Thorac Soc"},{"issue":"1","key":"10.1016\/j.pupt.2006.05.005_bib32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/089426804322994451","article-title":"Deposition of Foradil P in human lungs: comparison of in vitro and in vivo data","volume":"17","author":"Meyer","year":"2004","journal-title":"J Aerosol Med"},{"issue":"6","key":"10.1016\/j.pupt.2006.05.005_bib33","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1046\/j.1365-2125.2003.01893.x","article-title":"Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications","volume":"56","author":"Labiris","year":"2003","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.pupt.2006.05.005_bib34","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1046\/j.1365-2125.2003.01892.x","article-title":"Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications","volume":"56","author":"Labiris","year":"2003","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl. 1","key":"10.1016\/j.pupt.2006.05.005_bib35","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1089\/08942680150506303","article-title":"The influence of lung deposition on clinical response","volume":"14","author":"Pritchard","year":"2001","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.pupt.2006.05.005_bib36","unstructured":"US Department of Health and Human Services. National Institutes of Health, National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program. Expert Panel Report: guidelines for the diagnosis and management of asthma. Update on selected topics 2002. NIH Publication No. 02-5074, June 2003. Available at: www.nhlbi.nih.gov\/guidelines\/asthma\/asthupdt.htm"},{"issue":"6","key":"10.1016\/j.pupt.2006.05.005_bib37","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1081\/JAS-120018776","article-title":"Management of the acute exacerbation of asthma","volume":"40","author":"Roy","year":"2003","journal-title":"J Asthma"},{"issue":"10","key":"10.1016\/j.pupt.2006.05.005_bib38","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1053\/rmed.2002.1348","article-title":"A new HFA-134a propellant in the administration of inhaled BDP via the Jet\u00ae spacer: controlled clinical trial vs. the conventional CFC","volume":"96","author":"Vondra","year":"2002","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.pupt.2006.05.005_bib39","first-page":"107","article-title":"Equivalent efficacy and safety of a new HFA-134a formulation of BDP compared with the conventional CFC in adult asthmatics","volume":"12","author":"Anderson","year":"2002","journal-title":"J Invest Allergol Clin Immunol"},{"issue":"4","key":"10.1016\/j.pupt.2006.05.005_bib40","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1089\/08942680260473489","article-title":"Effects on lung function, symptoms, and bronchial hyperreactivity of low-dose inhaled beclomethasone dipropionate given with HFA-134a or CFC propellant","volume":"15","author":"Woodcock","year":"2002","journal-title":"J Aerosol Med"},{"issue":"10","key":"10.1016\/j.pupt.2006.05.005_bib41","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2165\/00044011-200222100-00002","article-title":"Efficacy and tolerability of a new non-extrafine formulation of beclomethasone HFA-134a in patients with asthma","volume":"22","author":"Rocca-Serra","year":"2002","journal-title":"Clin Drug Invest"},{"issue":"3","key":"10.1016\/j.pupt.2006.05.005_bib42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1089\/08831870260093852","article-title":"Assessment of efficacy and systemic safety of a new chlorofluorocarbon-free formulation of inhaled beclomethasone dipropionate in asthmatic children","volume":"15","author":"Lee","year":"2002","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.pupt.2006.05.005_bib43","unstructured":"Acerbi D, Poli G, Nollevaux F. Comparative evaluation of HPA function after repeated treatment with BDP CFC or BDP HFA pMDIs. Pharmaceuticals Sciences Fair & Exhibition, Nice, France, 12\u201317 June, 2005."},{"key":"10.1016\/j.pupt.2006.05.005_bib44","unstructured":"Brambilla G, Church T, Ganderton D, et al. Budesonide 200 HFA Modulite\u2122 Delivery from the Chiesi Jet\u2122. Presented at the Nasal & Pulmonary Drug Delivery VII, Barcelona, Spain, September 15\u201317, 2003."},{"issue":"Suppl. D","key":"10.1016\/j.pupt.2006.05.005_bib45","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.rmed.2003.10.004","article-title":"Equivalent asthma control and systemic safety of inhaled budesonide delivered via HFA-134a or CFC propellant in a broad range of doses","volume":"97","author":"Grzelewska-Rzymowska","year":"2003","journal-title":"Respir Med"},{"issue":"Suppl. 1","key":"10.1016\/j.pupt.2006.05.005_bib46","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000083688","volume":"72","author":"Bousquet","year":"2005","journal-title":"Respiration"},{"issue":"Suppl. 1","key":"10.1016\/j.pupt.2006.05.005_bib47","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000083687","article-title":"A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients","volume":"72","author":"Bousquet","year":"2005","journal-title":"Respiration"},{"issue":"Suppl. 1","key":"10.1016\/j.pupt.2006.05.005_bib48","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000083690","article-title":"A randomized, double-blind, double-dummy, safety crossover trial comparing cumulative doses up to 96\u03bcg of formoterol delivered via an HFA-134a-propelled pMDI vs. same cumulative doses of formoterol DPI and placebo in asthmatic patients","volume":"72","author":"Molimard","year":"2005","journal-title":"Respiration"},{"issue":"Suppl. 1","key":"10.1016\/j.pupt.2006.05.005_bib49","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000083689","volume":"72","author":"Dusser","year":"2005","journal-title":"Respiration"},{"issue":"Suppl. 45","key":"10.1016\/j.pupt.2006.05.005_bib50","first-page":"473s","article-title":"Acceptability and efficacy of beclomethasone dipropionate (Beclojet HFA\u00ae) and fluticasone dipropionate (Flixotide HFA\u00ae, FDP) associated with the Volumatic\u2122 spacer in adults with mild to moderate persistent asthma [abstract plus poster]","volume":"22","author":"Huchon","year":"2003","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.pupt.2006.05.005_bib51","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF03256622","article-title":"Formoterol: a review of its use in chronic obstructive pulmonary disease","volume":"1","author":"Cheer","year":"2002","journal-title":"Am J Respir Med"},{"issue":"3","key":"10.1016\/j.pupt.2006.05.005_bib52","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1034\/j.1399-3003.1999.14c24.x","article-title":"Formoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma","volume":"14","author":"Bouros","year":"1999","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.pupt.2006.05.005_bib53","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/BF03256655","article-title":"Combination therapy with single inhaler budesonide\/formoterol compared with high dose of fluticasone propionate alone in patients with moderate persistent asthma","volume":"2","author":"Bateman","year":"2003","journal-title":"Am J Respir Med"},{"issue":"5","key":"10.1016\/j.pupt.2006.05.005_bib54","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.rmed.2003.07.010","article-title":"Adjustable and fixed dosing with budesonide\/formoterol via a single inhaler in asthma patients: the ASSURE study","volume":"98","author":"Ind","year":"2004","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.pupt.2006.05.005_bib55","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1164\/rccm.200407-884OC","article-title":"Budesonide\/formoterol combination therapy as both maintenance and reliever medication in asthma","volume":"171","author":"O\u2019Byrne","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.pupt.2006.05.005_bib56","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1515\/IJAMH.2004.16.2.91","article-title":"Budesonide and formoterol in a single inhaler controls asthma in adolescents","volume":"16","author":"Pohunek","year":"2004","journal-title":"Int J Adolesc Med Health"},{"issue":"12","key":"10.1016\/j.pupt.2006.05.005_bib57","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1345\/aph.1C124","article-title":"Combined budesonide\/formoterol turbuhaler treatment of asthma","volume":"36","author":"Remington","year":"2002","journal-title":"Ann Pharmacother"},{"issue":"6","key":"10.1016\/j.pupt.2006.05.005_bib58","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1053\/rmed.2003.1504","article-title":"One-year safety and efficacy of budesonide\/formoterol in a single inhaler (Symbicort Turbuhaler) for the treatment of asthma","volume":"97","author":"Rosenhall","year":"2003","journal-title":"Respir Med"},{"key":"10.1016\/j.pupt.2006.05.005_bib59","doi-asserted-by":"crossref","unstructured":"Ni Chroinin M, Greenstone IR, Ducharme FM. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults. The Cochrane Database of Systematic Reviews 2004, Issue 4, Art. No. CD005307. Doi:10.1002\/14651858.CD005307.","DOI":"10.1002\/14651858.CD005307"},{"key":"10.1016\/j.pupt.2006.05.005_bib60","unstructured":"Chiesi Farmaceutici SpA, Data on File. 2004."},{"issue":"4","key":"10.1016\/j.pupt.2006.05.005_bib61","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2165\/00003495-200464040-00006","article-title":"Budesonide\/formoterol: in chronic obstructive pulmonary disease","volume":"64","author":"Reynolds","year":"2004","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.pupt.2006.05.005_bib62","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1742-1241.2003.tb10590.x","article-title":"State of the art in beta2-agonist therapy: a safety review of long-acting agents","volume":"57","author":"Rabe","year":"2003","journal-title":"Int J Clin Pract"},{"issue":"1","key":"10.1016\/j.pupt.2006.05.005_bib63","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1183\/09031936.03.00031402","article-title":"Efficacy and safety of budesonide\/formoterol in the management of chronic obstructive pulmonary disease","volume":"21","author":"Szafranski","year":"2003","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.pupt.2006.05.005_bib64","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.rmed.2004.11.006","article-title":"COPD, a multicomponent disease: implications for management","volume":"99","author":"Agusti","year":"2005","journal-title":"Respir Med"},{"issue":"2 Suppl. 1","key":"10.1016\/j.pupt.2006.05.005_bib65","doi-asserted-by":"crossref","first-page":"138S","DOI":"10.1378\/chest.126.2_suppl_1.138S","article-title":"Therapeutic responses in asthma and COPD corticosteroids","volume":"126","author":"Larj","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2006.05.005_bib66","doi-asserted-by":"crossref","unstructured":"Nannini L, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long acting beta-agonist in one inhaler for chronic obstructive pulmonary disease. The Cochrane Database of Systematic Reviews 2004, Issue 3, Art. No. CD003794. Doi:10.1002\/14651858.CD003794.pub2","DOI":"10.1002\/14651858.CD003794.pub2"},{"issue":"3","key":"10.1016\/j.pupt.2006.05.005_bib67","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.pupt.2004.01.001","article-title":"Onset of action of formoterol\/budesonide in single inhaler vs. formoterol in patients with COPD","volume":"17","author":"Cazzola","year":"2004","journal-title":"Pulm Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.pupt.2006.05.005_bib68","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0163-7258(02)00324-8","article-title":"Therapy of chronic obstructive pulmonary disease","volume":"97","author":"Barnes","year":"2003","journal-title":"Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.pupt.2006.05.005_bib69","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1053\/rmed.2002.1455","article-title":"Bronchodilator effect of an inhaled combination therapy with salmeterol+fluticasone and formoterol+budesonide in patients with COPD","volume":"97","author":"Cazzola","year":"2003","journal-title":"Respir Med"},{"issue":"11","key":"10.1016\/j.pupt.2006.05.005_bib70","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.2165\/00003495-200161110-00001","article-title":"Should inhaled corticosteroids be used in the long term treatment of chronic obstructive pulmonary disease?","volume":"61","author":"Burge","year":"2001","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.pupt.2006.05.005_bib71","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1164\/ajrccm.163.5.2101039","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI\/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary","volume":"163","author":"Pauwels","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2006.05.005_bib72","unstructured":"European Agency for the Evaluation of Medicinal Products: Committee for Proprietary Medicinal Products Meeting of 21\u201323 January 2003. Press Release, 2003. Available at: http:\/\/www.emea.eu.int\/pdfs\/human\/press\/pr\/029403en.pdf"},{"issue":"6","key":"10.1016\/j.pupt.2006.05.005_bib73","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1183\/09031936.04.00081604","article-title":"Combination therapy with maintenance budesonide and formoterol in COPD","volume":"24","author":"Medford","year":"2004","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.pupt.2006.05.005_bib74","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1023\/A:1015853824722","article-title":"Pulmonary delivery of peptide drugs: effect of particle size on bioavailability of leuprolide acetate in healthy male volunteers","volume":"7","author":"Adjei","year":"1990","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.pupt.2006.05.005_bib75","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1089\/15209150050025131","article-title":"Pulmonary insulin administration using the AERx system: physiological and physicochemical factors influencing insulin effectiveness in healthy fasting subjects","volume":"2","author":"Farr","year":"2000","journal-title":"Diabetes Technol Ther"},{"issue":"7","key":"10.1016\/j.pupt.2006.05.005_bib76","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/1520-6017(200007)89:7<940::AID-JPS11>3.0.CO;2-B","article-title":"The ascent of pulmonary drug delivery","volume":"89","author":"Gonda","year":"2000","journal-title":"J Pharm Sci"}],"container-title":["Pulmonary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553906000538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553906000538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,7]],"date-time":"2023-05-07T16:01:47Z","timestamp":1683475307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553906000538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":76,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["S1094553906000538"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2006.05.005","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2007,6]]}}}